Deals

Discovery & Translation

Politics, Policy & Law

Podcast


<div class="articleContainer"><div class="articleWrapper"><div class="articleContent"><h1 class="text title" doc-editable="text" data-component-id="doc-1fh3me1dm0"><span style="background-color: rgb(255, 255, 255);"><span data-text-edit-color style="color: rgb(29, 28, 29);">BioCentury&#x2019;s 2025-26 picks and predictions. Plus: BioMarin and more biotech ICYMI &#x2014; a BioCentury podcast</span></span></h1><h2 class="title-bottom webtitle" doc-editable="title" data-component-id="doc-1fh3men3r0">Our analysts choose their highlights of the year &#x2014; and forecast what&#x2019;s next for biopharma in 2026</h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1fh3me7lj0">
    <span class="ng-tns-c17-4" doc-editable="text">By Jeff Cranmer, Executive Editor</span>
</div><div class="date" data-component-id="doc-1fh3mec8j0">
  <span class="byline" doc-editable="text"></span>
</div><div class="embed" data-doc-label="Embed" data-component-id="doc-1jdls94b60">
    <div doc-html="html"><div id="buzzsprout-player-18429110"></div></div>
</div><p class="text body" doc-editable="text" data-component-id="doc-1fh3mg5il0">This past year was an inflection point for biotech: The markets woke up, M&amp;A and China had strong showings, drug development offered key trends, and new leadership at FDA shuffled the regulatory deck. On the latest <i>BioCentury This Week</i> podcast, BioCentury&#x2019;s analysts make their <a href="https://www.biocentury.com/article/657885">picks</a> for the biggest biopharma readouts, deals and regulatory and policy moves of 2025 and what they are forecasting for the year ahead.</p><p class="text body" doc-editable="text" data-component-id="doc-1jdmancsb0">The analysts also recap biotech highlights of the past two weeks, including the &#x24;4.8 billion <a href="https://www.biocentury.com/article/657924">takeout</a> of Amicus Therapeutics Inc. (NASDAQ:FOLD) by&#xa0;BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).</p><figure class="bannerimage_hidden hide _fit-frame-height-to-content" data-tap-fullscreen data-component-id="doc-1jdls9e2r0">
    <div doc-image="image" doc-link="hyperlink" style="display: block; height: 0px; overflow: hidden; padding-bottom: 40.6977%; background-image: url(https://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/cmjrxi3636sqh07oaec3y6tbi); background-position: 50% 50%;"></div>
    <figcaption style="color:#929292; font-size: 10px; text-align: right;" doc-editable="caption"></figcaption>
</figure><figure class="thumbnail_hidden hide _fit-frame-height-to-content _caption-none" data-tap-fullscreen data-component-id="doc-1fh3mhrcr0">
    <div doc-image="image" doc-link="hyperlink" style="display: block; height: 0px; overflow: hidden; padding-bottom: 100%; background-image: url(https://us-west-2-biocentury.graphassets.com/AqjgGpburRt67lm6SEY2Oz/cmjrxj7ze6xtg07mrpf1ni1ag); background-position: 50% 50%;"></div>
    <figcaption doc-editable="caption"></figcaption>
</figure></div></div></div>


This past year was an inflection point for biotech: The markets woke up, M&amp;A and China had strong showings, drug development offered key trends, and ne...

BioCentury’s 2025-26 picks and predictions. Plus: BioMarin and more biotech ICYMI — a BioCentury podcast

Our analysts choose their highlights of the year — and forecast what’s next for biopharma in 2026

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Discovery & Translation Analysis

Hot Topics

BioCentury Podcasts 

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data Coverage

BCIQ Data

All Events

BioCentury's JPM Guide 2026

JPM Guide 2026

East-West Healthcare Reception

At the East-West Summit, you will meet key players looking to globalize innovation from across Asia.